New PET tracer aims to reveal which cancers will respond to immunotherapy

NCT ID NCT07140315

Recruiting now Diagnosis Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This early-phase trial tests a new radioactive imaging agent, [18F]DK222, in 6 people with non-small cell lung cancer or urothelial cancer. The agent is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. Researchers want to see if the agent is safe, how it moves through the body, and how much radiation it gives off. This is not a treatment—it is a way to potentially improve cancer imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]DK222 radiotracer
What this could lead to: If successful, this could lead to a better way to see which cancers might respond to immunotherapy, helping doctors choose the right treatment.
What could go wrong: This is a very early, small study with only 6 people. The imaging agent may not work as hoped, or safety issues could arise. It is not a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER UROTHELIAL CANCER

Contacts and locations

Locations

Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.